Trial Information
Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab
Inclusion Criteria:
- Histopathologically proven diagnosis of GBM in the past with MRI findings compatible
with disease recurrence. Multifocal disease is permitted.
- Must have had prior treatment with standard doses of Temodar
- KPS >50; ECOG <3
- Predicted life expectancy of > 3 months
- Study entry must be within 5 weeks of surgical resection
Exclusion Criteria:
- Prior exposure to VEGF inhibitors or Irinotecan
- Intracranial bleed as defined by CT or MRI less than 6 months prior to entry
- GI bleed less than 6 months prior to entry
- Uncontrolled concurrent illness that would limit compliance with study requirements
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To assess disease free survival
Outcome Time Frame:
6 and 12 months
Safety Issue:
No
Principal Investigator
Margie Gerena-Lewis, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cincinnati
Authority:
United States: Institutional Review Board
Study ID:
08081101
NCT ID:
NCT00984438
Start Date:
June 2009
Completion Date:
June 2010
Related Keywords:
- Glioblastoma Multiforme
- Glioblastoma
Name | Location |
University of Cincinnati |
Cincinnati, Ohio 45267-0502 |